510(k) · Cleared
ClearedXtag CF60 Kit V2
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
Luminex Molecular Diagnostics, Inc. · NUA System, Cystic Fibrosis Transmembrane Conductance Regulator, Gene Mutation Detection
Cleared on Dec 11, 2009 as substantially equivalent to DEN050004 (Tm Bioscience Corporation, 2005) and 1 other predicate after a 352-day review. Its family tree reaches back 2 generations to 2005. 2 later devices descend from it.
- Decided
- Dec 11, 2009
- Review
- 352 days
- Class
- Class II
- Product code
- NUA
- Recalls
- None
- Predicates
- 2
Its longest line of descent runs back 2 generations to DEN050004 (2005). 2 later devices descend from it, 2 citing it directly.
- Root · 2 generations backDEN050004 Tag-IT Cystic Fibrosis KitTm Bioscience Corporation · 2005
- 1 generation backK060627 Tag-IT Cystic Fibrosis KitTm Bioscience Corporation · 2006
- This deviceK083845 Xtag CF60 Kit V2Luminex Molecular Diagnostics, Inc. · 2009
- Descendant · cites it directly · 0 of its ownK124006 Illumina Miseqdx Cystic Fibrosis 139-Variant AssayIllumina, Inc. · 2013
- Descendant · cites it directly · 0 of its ownK132750 Illumina Miseqdx Cystic Fibrosis Clinical Sequencing AssayIllumina, Inc. · 2013 · Recalled
Most influential descendants
Showing 2 of 2 · See allView FIG. 1 as a table
Line of descent and top descendants
| Generation | Number | Device | Applicant | Decided | Recalls |
|---|---|---|---|---|---|
| −2 | DEN050004 | Tag-IT Cystic Fibrosis Kit | Tm Bioscience Corporation | 2005 | — |
| −1 | K060627 | Tag-IT Cystic Fibrosis Kit | Tm Bioscience Corporation | 2006 | — |
| 0 (this device) | K083845 | Xtag CF60 Kit V2 | Luminex Molecular Diagnostics, Inc. | 2009 | — |
| +1 | K124006 | Illumina Miseqdx Cystic Fibrosis 139-Variant Assay | Illumina, Inc. | 2013 | — |
| +1 | K132750 | Illumina Miseqdx Cystic Fibrosis Clinical Sequencing Assay | Illumina, Inc. | 2013 | 2 |
Descendants by year cleared
| Year cleared | Devices | With a Class I recall |
|---|---|---|
| 2013 | 2 | 0 |
Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in NUA? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
- Candidate predicates for a device like this, rankedin the report
- Recall history across each candidate’s familyin the report
What was it cleared against? (2)
Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.
| Type | Number | Device | Decided |
|---|---|---|---|
| * | DEN050004 | Tag-IT Cystic Fibrosis Kit Our reading of the summary gave K043011, which is not in FDA’s 510(k) list. The device the summary names is FDA’s De Novo DEN050004, Tag-IT Cystic Fibrosis Kit (Tm Bioscience Corporation), granted May 9, 2005; older De Novo requests were first filed under a 510(k) number, so this links to the grant. | 2005 |
| * | K060627 | Tag-IT Cystic Fibrosis KitSummary page 2…hycoerythrin Conjugate Substantial Equivalence Information: 1. Predicatedevice name(s): xTAG® Cystic Fibrosis kit 2. Predicate510(k) number(s): k04301 1, k060627 5 10(k) summary for xTAG® CFTR 60 kit v2 Page 2 of 5 Luminex Mol… | 2006 |
What descends from it? (2)
2 later devices cite it directly; ranked here by how many devices descend from each in turn.
Has anything in its family been recalled? (0 Class I)
No FDA recall names this device.
No ancestor or descendant has a Class I recall.
What does this lineage say?
- The line of descent spans 4 years and passes through 2 companies; a new generation was cleared every 3.5 years on median.
- None of the 2 ancestors has a recall.
- Of its descendants, K124006 (Illumina, Inc., 2013) has gone furthest, with 0 descendants of its own.
- 5 other devices also cite its predicate DEN050004.
How does its category compare?
All NUA devicesNUA System, Cystic Fibrosis Transmembrane Conductance Regulator, Gene Mutation Detection: FDA decisions, review times, recalls and adverse event reports over 20 years. 2009, this device’s year, is highlighted.
FDA decisions per year · NUA
2in 2016
2026 to Oct 25, outlined.
Median 510(k) review, days · NUA
254in 2009
Receipt to decision; years with fewer than 3 clearances left blank.
Recalls per year · NUA
No recall names NUA since 2007.
Adverse event reports per year · NUA
1in 2013
MAUDE reports naming product code NUA, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 1 | — | 0 | 0 |
| 2008 | 1 | — | 0 | 0 |
| 2009 | 4 | 254 | 0 | 0 |
| 2010 | 0 | — | 0 | 0 |
| 2011 | 0 | — | 0 | 0 |
| 2012 | 0 | — | 0 | 0 |
| 2013 | 0 | — | 0 | 1 |
| 2014 | 0 | — | 0 | 0 |
| 2015 | 0 | — | 0 | 0 |
| 2016 | 2 | — | 0 | 0 |
| 2017 | 0 | — | 0 | 0 |
| 2018 | 0 | — | 0 | 0 |
| 2019 | 0 | — | 0 | 0 |
| 2020 | 0 | — | 0 | 0 |
| 2021 | 0 | — | 0 | 0 |
| 2022 | 0 | — | 0 | 0 |
| 2023 | 0 | — | 0 | 0 |
| 2024 | 0 | — | 0 | 0 |
| 2025 | 0 | — | 0 | 0 |
| 2026 | 0 | — | 0 | — |
What is it indicated for?
The xTAG® Cystic Fibrosis 60 kit v2 is a device used to simultaneously detect and identify a panel of mutations and variants in the cystic fibrosis transmembrane conductance regulator (CFTR) gene in human blood specimens. The panel includes mutations and variants currently recommended by the American College of Medical Genetics and American College of Obstetricians and Gynecologists (ACMG/ACOG) plus some of the world's most common and North American…
Read the full statement (135 words)
The xTAG® Cystic Fibrosis 60 kit v2 is a device used to simultaneously detect and identify a panel of mutations and variants in the cystic fibrosis transmembrane conductance regulator (CFTR) gene in human blood specimens. The panel includes mutations and variants currently recommended by the American College of Medical Genetics and American College of Obstetricians and Gynecologists (ACMG/ACOG) plus some of the world's most common and North American prevalent mutations. The xTAG Cystic Fibrosis 60 kit v2 is a qualitative genotyping test which provides information intended to be used for carrier testing in adults of reproductive age, as an aid in newborn screening, and in confirmatory diagnostic testing in newborns and children:
The kit is not indicated for use in fetal diagnostic or pre-implantation testing. This kit is also not indicated for stand-alone diagnostic purposes.
Indications for use as stated in the FDA summary.
https://510kreport.com/device/K083845 · printed Nov 4, 2026
Cite this page
510(k) Report. “K083845: Xtag CF60 Kit V2.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 4, 2026. https://510kreport.com/device/K083845
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
- Lineage and recalls computed Nov 3, 2026
- Page last updated Nov 3, 2026